Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and abemaciclib were recently approved for breast cancer treatment in vari...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drugs
Autors principals: Braal, C. Louwrens, Jongbloed, Elisabeth M., Wilting, Saskia M., Mathijssen, Ron H. J., Koolen, Stijn L. W., Jager, Agnes
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952354/
https://ncbi.nlm.nih.gov/pubmed/33369721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01461-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars